文献速递泌尿生殖与妇科肿瘤放疗

前列腺癌盆腔淋巴结照射后放射性淋巴细胞减少症

Radiation-related Lymphopenia after Pelvic Nodal Irradiation for Prostate Cancer.
PubMed 文献 · Adv Radiat Oncol · 2019-01-25

本研究回顾性分析886例接受放疗的前列腺癌患者,其中36例接受盆腔淋巴结照射(PNI)、95例未接受。PNI组放射性淋巴细胞减少症(RRL)发生率为61.1%,非PNI组为26.3%(P<.001)。多因素分析显示PNI状态是RRL的显著预测因素(HR 3.42,95%CI 1.22-9.61,P<.001),但RRL未显著预测生化无进展生存、远处转移或总生存,作者指出事件数可能不足。

要点

  • PNI组RRL发生率为61.1%,非PNI组为26.3%(P<.001)。
  • 多因素分析中PNI状态预测RRL的HR为3.42(95%CI 1.22-9.61,P<.001)。
  • RRL未显著预测生化无进展生存、远处转移或总生存,但事件数可能不足。

核心结论

  • PNI患者发生RRL的风险更高,这与其它显示治疗体积增加与RRL发生率升高相关的研究一致。
  • 作者认为,RRL对临床结局不良影响的证据不断增加,支持了本研究发现的意义,并建议进一步研究RRL作为PNI潜在危害的可能性,该危害可能影响PNI临床试验结果的解读。

研究设计与样本

  • 回顾性分析2006年至2018年在本机构连续接受前列腺癌放疗的886例患者的电子病历。
  • 符合纳入条件的患者为在放疗开始前1年内及开始后3至24个月内具有总淋巴细胞计数的患者。
  • 主要结局为淋巴细胞减少症,次要结局为总生存和生化无进展生存。
  • 最终纳入36例接受PNI的患者和95例未接受PNI的患者。

主要发现

  • PNI组61.1%的患者发生RRL(中位随访总淋巴细胞计数<1000 cells/μL),非PNI组为26.3%(P<.001)。
  • 单因素分析中,初始前列腺特异性抗原水平、基线淋巴细胞减少、治疗方式、PNI状态、计划靶体积增加和雄激素剥夺治疗均为RRL的显著预测因素(P<.05)。
  • 多因素分析中,PNI状态是RRL的显著预测因素(HR 3.42,95%CI 1.22-9.61,P<.001),初始前列腺特异性抗原值(HR 1.05,95%CI 1.00-1.11,P=.006)和基线淋巴细胞减少(HR 8.32,95%CI 2.19-31.6,P=.007)也是显著预测因素。
  • 多因素分析中RRL未显著预测生化无进展生存、远处转移或总生存,但事件数可能不足以进行这些分析。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 多因素分析中RRL未显著预测生化无进展生存、远处转移或总生存,但事件数可能不足以进行这些分析。
  • 作者认为需要进一步研究RRL作为PNI潜在危害的可能性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Given the uncertainty with regard to the effectiveness of pelvic nodal irradiation (PNI) for prostate cancer, we aimed to determine whether patients with prostate cancer who are treated with PNI are at a higher risk of developing radiation-related lymphopenia (RRL). METHODS AND MATERIALS: The electronic charts of 886 consecutive patients treated with radiation therapy for prostate cancer between 2006 and 2018 at our institution were retrospectively analyzed. Qualifying patients were those with total lymphocyte counts within 1 year before and 3 to 24 months after the start of radiation therapy. Lymphopenia was the primary outcome, and overall survival and biochemical progression-free survival were secondary outcomes. RESULTS: Thirty-six patients with and 95 patients without PNI qualified for inclusion. In the PNI cohort, 61.1% of patients developed RRL (median follow-up total lymphocyte count < 1000 cells/μL) versus 26.3% of non-PNI patients (P < .001). On univariate analysis, initial prostate-specific antigen level, baseline lymphopenia, treatment modality, PNI status, increased planned target volume, and androgen deprivation therapy administration were all significant predictors of RRL (P < .05). On multivariate analysis, PNI status was a significant predictor of RRL (hazard ratio [HR], 3.42; 95% confidence interval [CI], 1.22-9.61; P < .001), as were initial prostate-specific antigen values (HR, 1.05; 95% CI, 1.00-1.11; P = .006) and baseline lymphopenia (HR, 8.32; 95% CI, 2.19-31.6; P = .007). RRL was not predictive for biochemical progression-free survival, distant metastasis, or overall survival on multivariate analysis, but the number of events was likely insufficient for these analyses. CONCLUSIONS: The higher risk of RRL among patients with PNI comports with other papers that show that increased treatment volumes are associated with higher rates of RRL. Mounting evidence for the adverse effects of RRL on clinical outcomes supports the significance of our findings and suggests that further studies are needed on RRL as a potential harm of PNI that may affect the interpretation of results from clinical trials of PNI.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Schad MD, Dutta SW, Muller DM, et al. Radiation-related Lymphopenia after Pelvic Nodal Irradiation for Prostate Cancer. Adv Radiat Oncol. 2019. PMID: 31011677. doi:10.1016/j.adro.2019.01.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。